Patents Assigned to Biotest AG
-
Patent number: 9334325Abstract: The present invention provides a pharmaceutical composition for treating an autoimmune disease comprising a pharmaceutically acceptable carrier and an agent capable of activating CD4+CD25+ regulatory T cells, wherein the composition is to be administered to a subject in a dose of the agent from 0.2 mg to 30 mg.Type: GrantFiled: September 13, 2010Date of Patent: May 10, 2016Assignee: BIOTEST AGInventors: Frank Osterroth, Silke Aigner, Matthias Germer, Christoph Uherek, Elmar Kraus, Andrea Wartenberg-Demand, Daniele Wolf, Sibylle Kaiser, Juergen Lindner, Christoph Bruecher, Benjamin Daelken
-
Patent number: 9289509Abstract: Disclosed are methods and treatment regimes that include the administration of immunconjugates targeting CD138 to combat diseases. The immunoconjugate is either used as the sole active ingredient, as part of a treatment regime or as part of an anticancer combination.Type: GrantFiled: May 5, 2010Date of Patent: March 22, 2016Assignees: Biotest AG, Immunogen Inc.Inventors: Frank Osterroth, Christoph Uherek, Christoph Bruecher, Benjamin Daelken, Andre Engling, Thomas Haeder, Andrea Wartenberg-Demand, Gabriele Niemann, Chantal Zuber, Niklas Czeloth, Silke Aigner, Steffen Zeng, Gregor Schulz
-
Patent number: 9243056Abstract: A process is provided for the preparation of an immunoglobulin composition from a plasma fraction having immunoglobulins, and antibody preparations prepared utilizing the process.Type: GrantFiled: October 19, 2012Date of Patent: January 26, 2016Assignee: BIOTEST AGInventors: Wolfgang Moeller, Dieter Rudnick, Oliver Maneg, Michael Rodemer, Herbert Dichtelmueller, Eckhard Flechsig
-
Patent number: 9221914Abstract: Disclosed is a human murine chimeric antibody targeting CD138 which substantially retains the antigen binding region of its murine counterpart. The engineered antibody displays improved binding affinities to the antigen and/or more homogenous binding to target cells relative to its murine counterpart. A constant region of the immunoglobulin heavy chain is preferably an IgG4 isotype constant region.Type: GrantFiled: December 23, 2008Date of Patent: December 29, 2015Assignee: BIOTEST AGInventors: Elmar Kraus, Christoph Bruecher, Benjamin Daelken, Matthias Germer, Steffen Zeng, Frank Osterroth, Christoph Uherek, Silke Aigner, Gregor Schulz
-
Patent number: 9011864Abstract: Disclosed are methods, compositions and kits for improving targeting, in particular tumor targeting, of immunoconjugates. The method and composition relies on the sequestration of non-target cells that also express the antigen the immunoconjugate targets. Sequestration of those non-target cells in a variety of ways is disclosed. The methods, compositions and kits allow appropriate sequestration of non-target cells while maintaining a high degree of effectiveness of the immunoconjugates against target cells.Type: GrantFiled: December 23, 2008Date of Patent: April 21, 2015Assignees: Biotest AG, Immunogen, Inc.Inventors: Gregor Schulz, Christoph Bruecher, Frank Osterroth, Steffen Zeng, Christoph Uherek, Silke Aigner, Benjamin Daelken, Markus Ruehle, Elmar Kraus
-
Publication number: 20150064170Abstract: An antibody preparation suitable for intravenous administration in humans includes IgG, IgA and at least 5% IgM antibodies by weight of the total amount of antibodies. The preparation is prepared from human plasma, has specific complement activating activity, and, in an in vitro assay with human serum suitable to determine the ability of the antibody preparation to activate complement unspecifically, the antibody preparation generates substantially no C5a and/or substantially no C3a. The antibody preparation can have medical uses.Type: ApplicationFiled: October 31, 2014Publication date: March 5, 2015Applicant: BIOTEST AGInventors: Wolfgang Möller, Dieter Rudnick, Oliver Maneg, Michael Rodemer, Matthias Germer, Veit Braun
-
Patent number: 8956607Abstract: Provided is a humanized or chimeric antibody or fragment thereof capable of binding to interleukin-10 (IL-10), wherein said antibody or fragment thereof: (i) binds to the same region of IL-10 as the IL-10 receptor ?(IL-I10Ra) and is not capable of binding IL-10 when the IL-10 is bound to the IL- 10 receptor; and (ii) binds to IL-10 in homodimeric form by binding a discontinuous epitope comprising residues of both monomers. Further provided are related products and methods involving the use of the antibody or fragment thereof.Type: GrantFiled: November 30, 2010Date of Patent: February 17, 2015Assignee: Biotest AGInventors: Frank Osterroth, Christoph Uherek, Christoph Bruecher, Peter Röttgen, Benjamin Daelken, André Engling, Chantal Zuber, Niklas Czeloth
-
Patent number: 8900806Abstract: An antibody preparation suitable for intravenous administration in humans includes IgG, IgA and at least 5% IgM antibodies by weight of the total amount of antibodies. The preparation is prepared from human plasma, has specific complement activating activity, and, in an in vitro assay with human serum suitable to determine the ability of the antibody preparation to activate complement unspecifically, the antibody preparation generates substantially no C5a and/or substantially no C3a. The antibody preparation can have medical uses.Type: GrantFiled: October 19, 2012Date of Patent: December 2, 2014Assignee: Biotest AGInventors: Wolfgang Moeller, Dieter Rudnick, Oliver Maneg, Michael Rodemer, Matthias Germer, Veit Braun
-
Patent number: 8852871Abstract: Provided is a humanized or chimeric antibody or fragment thereof capable of binding to interleukin-10 (Th-10), wherein said antibody or fragment thereof is capable of being administered to a subject in the absence of an intolerable increase in the level of pro-inflammatory cytokines. Further provided are methods of treatment involving the use of the antibody or fragment thereof.Type: GrantFiled: November 30, 2010Date of Patent: October 7, 2014Assignee: Biotest AGInventors: Frank Osterroth, Christoph Uherek, Christoph Bruecher, Peter Röttgen, Benjamin Daelken, André Engling, Chantal Zuber, Niklas Czeloth, Andrea Wartenberg-Demand, Marcus Gutscher, Judith Wessels-Kranz
-
Patent number: 8840898Abstract: Immunoconjugates comprising a targeting agent selectively targeting cell-surface expressed syndecan-1 and at least one effector molecule as well as in vitro and in vivo methods of using those immunocomjugates are disclosed. The effector molecule may have, in its native form, high non-selective cytotoxicity, but substantially no non-selective cytotoxicity when part of said immunoconjugate. Targeting agents include the antibody B-B4 as well as other agents that bind cell-surface expressed syndecan-1.Type: GrantFiled: April 16, 2007Date of Patent: September 23, 2014Assignees: Biotest AG, ImmunoGen, Inc.Inventor: Viktor S. Goldmakher
-
Publication number: 20140220008Abstract: A humanized antibody derived from mouse monoclonal anti-CD4 antibody B-F5 is able to activate CD25+CD4+ regulatory T cells and is useful for preparing immunosuppressive compositions.Type: ApplicationFiled: February 10, 2014Publication date: August 7, 2014Applicant: BIOTEST AGInventors: John Wijdenes, Helmut Jonuleit
-
Patent number: 8685651Abstract: A humanized antibody derived from mouse monoclonal anti-CD4 antibody B-F5 is able to activate CD25+CD4+ regulatory T cells and is useful for preparing immunosuppressive compositions.Type: GrantFiled: February 25, 2009Date of Patent: April 1, 2014Assignee: Biotest AGInventors: John Wijdenes, Helmut Jonuleit
-
Patent number: 8673304Abstract: A humanized antibody derived from mouse monoclonal anti-CD4 antibody B-F5 is able to activate CD25+CD4+ regulatory T cells and is useful for preparing immunosuppressive compositions.Type: GrantFiled: February 25, 2009Date of Patent: March 18, 2014Assignee: Biotest AGInventors: John Wijdenes, Helmut Jonuleit
-
Publication number: 20140010828Abstract: Disclosed is a method and composition for treating a disease associated with target cells expressing CD138 in a multiple dose regimen. An immunoconjugate comprising an engineered targeting antibody targeting CD138 expressing cells and an effector molecule is administered in a multiple dose regimen. The multiple dose regimen comprises at least two doses and the aggregate dose administered within an active treatment cycle is an aggregate maximum tolerable dose (AMTD) or a fraction of the AMTD. The AMTD and/or said fraction exceeds the dose resulting in dose limiting toxicity (DLT) and/or exceeds the maximum tolerable dose (MTD) when the immunoconjugate is administered as a single dose, including as part of a multiple single dose regimen within said active treatment cycle.Type: ApplicationFiled: December 7, 2012Publication date: January 9, 2014Applicants: IMMUNOGEN, INC., BIOTEST AGInventors: Gregor Schulz, Frank Osterroth, Thomas Haeder, Christoph Bruecher, Gabriele Niemann, Andre Engling, Christoph Uherek, Benjamin Daelken, Andrea Wartenberg-Demand, Chantal Zuber, Marcus Gutscher, Katrin Bernoester, Martin Koenig
-
Patent number: 8586715Abstract: A humanized antibody derived from mouse monoclonal anti-CD4 antibody B-F5 is able to activate CD25+CD4+ regulatory T cells and is useful for preparing immunosuppressive compositions.Type: GrantFiled: October 7, 2008Date of Patent: November 19, 2013Assignee: Biotest AGInventors: John Wijdenes, Helmut Jonuleit
-
Patent number: 8440806Abstract: A humanized antibody derived from mouse monoclonal anti-CD4 antibody B-F5 is able to activate CD25+CD4+ regulatory T cells and is useful for preparing immunosuppressive compositions.Type: GrantFiled: February 25, 2009Date of Patent: May 14, 2013Assignee: Biotest AGInventors: John Wijdenes, Helmut Jonuleit
-
Publication number: 20130052208Abstract: A process is provided for the preparation of an immunoglobulin composition from a plasma fraction having immunoglobulins, and antibody preparations prepared utilizing the process.Type: ApplicationFiled: October 19, 2012Publication date: February 28, 2013Applicant: BIOTEST AGInventor: BIOTEST AG
-
Publication number: 20130045199Abstract: An antibody preparation suitable for intravenous administration in humans includes IgG, IgA and at least 5% IgM antibodies by weight of the total amount of antibodies. The preparation is prepared from human plasma, has specific complement activating activity, and, in an in vitro assay with human serum suitable to determine the ability of the antibody preparation to activate complement unspecifically, the antibody preparation generates substantially no C5a and/or substantially no C3a. The antibody preparation can have medical uses.Type: ApplicationFiled: October 19, 2012Publication date: February 21, 2013Applicant: BIOTEST AGInventor: Biotest AG
-
Publication number: 20120321618Abstract: Provided is a humanized or chimeric antibody or fragment thereof capable of binding to interleukin-10 (Th-10), wherein said antibody or fragment thereof is capable of being administered to a subject in the absence of an intolerable increase in the level of pro-inflammatory cytokines. Further provided are methods of treatment involving the use of the antibody or fragment thereof.Type: ApplicationFiled: November 30, 2010Publication date: December 20, 2012Applicant: BIOTEST AGInventors: Frank Osterroth, Christoph Uherek, Christoph Bruecher, Peter Röttgen, Benjamin Daelken, André Engling, Chantal Zuber, Niklas Czeloth, Andrea Wartenberg-Demand, Marcus Gutscher, Judith Wessels-Kranz
-
Publication number: 20120321617Abstract: Provided is a humanized or chimeric antibody or fragment thereof capable of binding to interleukin-10 (IL-10), wherein said antibody or fragment thereof: (i) binds to the same region of IL-10 as the 1L-10 receptor ? (IL-I10Ra) and is not capable of binding IL-10 when the IL-10 is bound to the IL-10 receptor; and (ii) binds to IL-10 in homodimeric form by binding a discontinuous epitope comprising residues of both monomers. Further provided are related products and methods involving the use of the antibody or fragment thereof.Type: ApplicationFiled: November 30, 2010Publication date: December 20, 2012Applicant: BIOTEST AGInventors: Frank Osterroth, Christoph Uherek, Christoph Bruecher, Peter Röttgen, Benjamin Daelken, André Engling, Chantal Zuber, Niklas Czeloth